Clinical Trials Logo

Clinical Trial Summary

This protocol proposes to investigate genetic factors that may be involved in the pathogenesis of adverse events of interest with selected covid-19 vaccines: vaccine-induced immune thrombotic thrombocytopenia, and neurological adverse events, such as Guillain-Barré syndrome, acute disseminated encephalomyelitis and transverse myelitis, with the intention of identifying useful biomarkers in identifying people at higher risk, thus reducing the occurrence of these serious adverse events (SAE).


Clinical Trial Description

Participants higher than 5 years old with no maximum age limit and both sexes, who had a serious adverse event after vaccination against Covid-19, such as Guillain-Barré syndrome, vaccine-induced immune thrombotic thrombocytopenia, transverse myelitis and Acute disseminated encephalomyelitis. Parents, siblings and/or sons of cases with SAE will have biological samples collected and stored; depending on the result of the study, they may have their samples analyzed later. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05630313
Study type Observational
Source The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Contact Patrícia de Oliveira, MD
Phone +55213882-2013
Email patricia.mouta@bio.fiocruz.br
Status Recruiting
Phase
Start date October 4, 2022
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Terminated NCT04053452 - Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome N/A
Recruiting NCT02582853 - sCD163 as a Potential Biomarker in Guillain- Barré Syndrome N/A
Completed NCT00056810 - Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Phase 2
Completed NCT05104762 - IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients Phase 2/Phase 3
Recruiting NCT03801135 - Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation N/A
Active, not recruiting NCT01655394 - Change of Nerve Conduction Properties in IVIg Dependent Neuropathies N/A
Completed NCT04927598 - Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
Completed NCT06334796 - Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology Early Phase 1
Not yet recruiting NCT04092140 - Neuromuscular Ultrasound in Correlation to Neurophysiological Findings
Not yet recruiting NCT04550611 - Mini-pool Intravenous Immunoglobulin (MP-IVIG) in Guillain-Barré Syndrome N/A
Withdrawn NCT03268304 - Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments
Not yet recruiting NCT05701189 - Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome Phase 2
Withdrawn NCT02459808 - Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome N/A
Completed NCT04752566 - A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome Phase 3
Completed NCT05292690 - An Assistive Powered Wheelchair: Stage 2 Trial
Not yet recruiting NCT06300359 - Prognostic Indicators of Gullian-Barre Syndrome
Completed NCT00575653 - Safety Study of GBS Following Menactra Meningococcal Vaccination N/A
Completed NCT05491096 - Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome N/A
Not yet recruiting NCT05114941 - Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome N/A
Completed NCT05945784 - Exploring Accessible Beauty for Individuals With Upper Extremity Deficits